Immunological factors in NSCLC patients with possible predictive and prognostic value under PDL-1 treatment-a pilot study
K. Domvri (Thessaloniki, Greece), N. Zogas (Thessaloniki, Greece), P. Zarogoulidis (Thessaloniki, Greece), K. Porpodis (Thessaloniki, Greece), E. Eleftheriadou (Thessaloniki, Greece), P. Chinelis (Thessaloniki, Greece), D. Bougiouklis (Thessaloniki, Greece), T. Tsiouda (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), K. Zarogoulidis (Thessaloniki, Greece)
Source: International Congress 2019 – Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Poster Discussion
Number: 369
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Domvri (Thessaloniki, Greece), N. Zogas (Thessaloniki, Greece), P. Zarogoulidis (Thessaloniki, Greece), K. Porpodis (Thessaloniki, Greece), E. Eleftheriadou (Thessaloniki, Greece), P. Chinelis (Thessaloniki, Greece), D. Bougiouklis (Thessaloniki, Greece), T. Tsiouda (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), K. Zarogoulidis (Thessaloniki, Greece). Immunological factors in NSCLC patients with possible predictive and prognostic value under PDL-1 treatment-a pilot study. 369
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: